Abstract
Evidence has shown that omalizumab is highly effective for the treatment of severe allergic asthma inadequately controlled on step 5 of BTS guideline. OBJECTIVE: To evaluate the efficacy of Omalizumab in carefully selected group of children with severe allergic asthma aged 6 -18 years. METHOD: This is a retrospective observational study of 19 children with severe allergic asthma treated with Omalizumab for a minimum of 4 months between 2011 and 2015.Number of severe exacerbations(requiring oral corticosteroids ≥3 days),unscheduled hospital visits,HDU/PICU admissions,inhaled corticosteroid (CS) dose,daily dose of maintenance oral prednisolone,FEV1% predicted,exhaled nitric oxide(FeNO) and Asthma Control Test(ACT) were recorded before and every 4 weeks after commencing treatment. RESULTS: 14/19(73%)continued Omalizumab beyond 16 weeks trial and 12/19(63%) beyond 52 weeks.There was a significant statistical reduction in the number of severe exacerbations, unscheduled hospital visits,HDU/PICU admissions and maintenance daily prednisolone 52 weeks after starting Omalizumab.There was no significant change of the inhaled CS dose,FEV1% predicted,ACT scoring and FeNO post starting Omalizumab. There is no significant difference between patients aged <12 and ≥12 years. CONCLUSION: This study demonstrated long-term clinical efficacy of Omalizumab as add-on therapy in carefully selected children with severe therapy resistant allergic asthma.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call